First-in-Man Noninvasive Initial Diagnostic Approach of Primary CNS Lymphoma Versus Glioblastoma Using PET With 18 F-Fludarabine and l -[methyl- 11 C]Methionine.
Adrenal Cortex Hormones
Brain Neoplasms
/ diagnostic imaging
Diagnosis, Differential
Fluorodeoxyglucose F18
Glioblastoma
/ diagnostic imaging
Humans
Lymphoma
/ diagnostic imaging
Methionine
Positron Emission Tomography Computed Tomography
Positron-Emission Tomography
Vidarabine
/ analogs & derivatives
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Aug 2022
01 Aug 2022
Historique:
pubmed:
30
4
2022
medline:
12
7
2022
entrez:
29
4
2022
Statut:
ppublish
Résumé
This study sought to assess 18 F-fludarabine ( 18 F-FLUDA) PET/CT's ability in differentiating primary central nervous system lymphomas (PCNSLs) from glioblastoma multiformes (GBMs). Patients harboring either PCNSL (n = 8) before any treatment, PCNSL treated using corticosteroids (PCNSLh; n = 10), or GBM (n = 13) were investigated with conventional MRI and PET/CT, using 11 C-MET and 18 F-FLUDA. The main parameters measured with each tracer were SUV T and T/N ratios for the first 30 minutes of 11 C-MET acquisition, as well as at 3 different times after 18 F-FLUDA injection. The early 18 F-FLUDA uptake within the first minute of injection was equally considered, whereas this parameter was combined with the later uptakes to obtain R FLUDA 2 and R FLUDA 3 ratios. No significant differences in 11 C-MET uptakes were observed among PCNSL, PCNSLh, and GBM. With 18 F-FLUDA, a clear difference in dynamic GBM uptake was observed, which decreased over time after an early maximum, as compared with that of PCNSL, which steadily increased over time, PCNSLh exhibiting intermediate values. The most discriminative parameters consisting of R FLUDA 2 and R FLUDA 3 integrated the early tracer uptake (first 60 seconds), thereby provided 100% specificity and sensitivity. 18 F-FLUDA was shown to likely be a promising radiopharmaceutical for differentiating PCNSL from other malignancies, although a pretreatment with corticosteroids might compromise this differential diagnostic ability. The diagnostic role of 18 F-FLUDA should be further investigating, along with its potential of defining therapeutic strategies in patients with PCNSL, while assessing the treatments' effectiveness.
Identifiants
pubmed: 35485864
doi: 10.1097/RLU.0000000000004238
pii: 00003072-202208000-00005
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Methionine
AE28F7PNPL
Vidarabine
FA2DM6879K
fludarabine
P2K93U8740
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
699-706Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest: none declared.
Références
Hoang-Xuan K, Bessell E, Bromberg J, et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol . 2015;16:e322–e332.
Anderson V, Perry C. Fludarabine: a review of its use in non-Hodgkin’s lymphoma. Drugs . 2007;67:1633–1657.
Guillouet S, Patin D, Tirel O, et al. Fully automated radiosynthesis of 2-F-18 fludarabine for PET imaging of low-grade lymphoma. Mol Imaging Biol . 2014;16:28–35.
Dhilly M, Guillouet S, Patin D, et al. 2-F-18 Fludarabine, a novel positron emission tomography (PET) tracer for imaging lymphoma: a micro-PET study in murine models. Mol Imaging Biol . 2014;16:118–126.
Hovhannisyan N, Dhilly M, Guillouet S, et al. Comparative analysis between F-18 Fludarabine-PET and F-18 FDG-PET in a murine model of inflammation. Mol Pharm . 2016;13:2136–2139.
Chantepie S, Hovhannisyan N, Guillouet S, et al. F-18 fludarabine PET for lymphoma imaging: first-in-humans study on DLBCL and CLL patients. J Nucl Med . 2018;59:1380–1385.
Hovhannisyan N, Fillesoye F, Guillouet S, et al. F-18 Fludarabine-PET as a promising tool for differentiating CNS lymphoma and glioblastoma: comparative analysis with F-18 FDG in human xenograft models. Theranostics . 2018;8:4563–4573.
Derlon JM, Chapon F, Noël MH, et al. Non-invasive grading of oligodendrogliomas: correlations between in vivo metabolic pattern and histopathology. Eur J Nucl Med . 2000;27:778–787.
Louis DN, Perrie A, Wesseling P, et al. The 2021 WHO classification of tumours of the central nervous system: a summary. Neuro Oncol . 2021;23:1231–1251.
Quincoces G, Lopez-Sanchez L, Sanchez-Martınez M, et al. Design and performance evaluation of single-use whole-sterile “plug & play” kits for routine automated production of C-11 choline and C-11 methionine with radiopharmaceutical quality. Appl Radiat Isot . 2010;68:2298–2301.
Kawase Y, Yamamoto Y, Kameyama R, et al. Comparison of C-11 Methionine PET and F-18 FDG PET in patients with primary central nervous system lymphoma. Mol Imaging Biol . 2011;13:1284–1289.
Haldorsen IS, Espeland A, Larsson EM. Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR . 2011;32:984–992.
Barajas RF Jr., Letterio S, Politi LS, et al. Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro Oncol . 2021;XX:1–16.
Kosaka N, Tsuchida T, Uematsu H, et al. F-18 FDG PET of common enhancing malignant brain tumors. AJR . 2008;190:W365–W369.
Kawai N, Zhen HN, Miyake K, et al. Prognostic value of pretreatment F-18 FDG PET in patients with primary central nervous system lymphoma: SUV-based assessment. J Neurooncol . 2010;100:225–232.
Makino K, Hirai T, Nakamura H, et al. Does adding F-18 FDG PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study. Ann Nucl Med . 2011;25:432–438.
Yamashita K, Yoshiura T, Hiwatashi A, et al. Differentiating primary CNS lymphoma from glioblastoma multiforme: assessment using arterial spin labelling, diffusion-weighted imaging, and F-18 fluorodeoxyglucose positron emission tomography. Neuroradiology . 2013;55:135–143.
Zou Y, Tong J, Leng H, et al. Diagnostic value of using F-18 FDG PET and PET/CT in immunocompetent patients with primary central nervous system lymphoma: a systematic review and meta-analysis. Oncotarget . 2017;8:41518–41528.
Zhou W, Wen J, Hua F, et al. F-18 FDG PET/CT in immunocompetent patients with primary central nervous system lymphoma: differentiation from glioblastoma and correlation with DWI. Eur J Radiol . 2018;104:26–32.
Comar D, Cartron JC, Mazière M, et al. Labelling and metabolism of L-[ methy l- 11 C]Methionine. Eur J Nucl Med . 1976;1:11–14.
Okada Y, Nihashi T, Fujii M, et al. Differentiation of newly diagnosed glioblastoma multiforme and intracranial diffuse large B-cell lymphoma using C-11 Methionine and F-18 FDG PET. Clin Nucl Med . 2012;37:843–849.
Ogawa T, Kanno I, Hatazawa J, et al. C-11 Methionine PET for follow-up of radiation therapy of primary lymphoma of the brain. Radiographics . 1994;14:101–110.
Costantini DL, Reza Vali R, McQuattie S, et al. A pilot study of F-18 FLT PET/CT in pediatric lymphoma. Int J Mol Imaging . 2016;6045894.
Lapa C, Lückerath K, Kleinlein I, et al. 68 Ga-Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in glioblastoma. Theranostics . 2016;6:428–434.
Herhaus P, Lipkova J, Lammer F, et al. CXCR4-targeted PET imaging of central nervous system B-cell lymphoma. J Nucl Med . 2020;61:1765–1771.